This strategy has been clinically adopted, as exemplified by Atezolizumab (anti-PD-L1), the exclusive Food and Drug Administration (FDA) approved immunotherapy for breast cancer, though its application remains limited to metastatic triple-negative breast cancer (TNBC) (49). Here, CD274 is linked to triple-negative breast carcinoma.